Dementia biotech Kinoxis raises $6.75 million with a $2.5m grant as cherry on top
Melbourne dementia drug developer Kinoxis secured $6.75 million equity led by Main Sequence plus a $2.5 million Medical Research Future Fund grant via CUREator+, funding trials of its agitation and pain drug candidates.